Filing Flows › Comparisons › UTHR vs NRIX
United Therapeutics vs Nurix Therapeutics: UTHR and NRIX compared
United Therapeutics is the larger company: $832M of revenue in its latest quarter (Q3 2026) against $673M for Nurix Therapeutics (Q3 FY26). Nurix Therapeutics is growing faster (85× against +4% a year earlier). Nurix Therapeutics is more profitable, with an operating margin of 83.1% against 37.0%.
Where the money goes: UTHR and NRIX
United Therapeutics (UTHR) · Q3 2026
United Therapeutics, Q3 2026: revenue $832M (+4% year over year), operating margin 37.0%, net earnings $259M, operating cash flow $306M. The chart follows the revenue to costs, profit and cash.
Nurix Therapeutics (NRIX) · Q3 FY26
Nurix Therapeutics, Q3 FY26: revenue $673M (85× year over year), operating margin 83.1%, net earnings $550M, operating cash flow $616M. The chart follows the revenue to costs, profit and cash.
| United Therapeutics (UTHR) | Nurix Therapeutics (NRIX) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q3 FY26 |
| Revenue | $832M | $673M |
| Revenue growth, Y/Y | +4% | 85× |
| Gross margin | 88.1% | — |
| Operating margin | 37.0% | 83.1% |
| Net earnings | $259M | $550M |
| Net margin | 31.1% | 81.7% |
| Operating cash flow | $306M | $616M |
| Free cash flow | $126M | $614M |
| Market value | $25.5B | $1.8B |
| P/E | 21.2× | 6.7× |
| Analysts’ mean target | $670.93 | $33.38 |
Where the revenue comes from
United Therapeutics
- Total Tyvaso: $504M (61%)
- Orenitram: $145M (17%)
- Remodulin: $122M (15%)
- Unituxin: $52.3M (6%)
Nurix Therapeutics
- License revenue: $653M (97%)
- Collaboration revenue: $19.9M (3%)
Questions
Which is bigger, United Therapeutics or Nurix Therapeutics?
United Therapeutics is the larger company: $832M of revenue in its latest quarter (Q3 2026) against $673M for Nurix Therapeutics (Q3 FY26).
Is United Therapeutics or Nurix Therapeutics growing faster?
Nurix Therapeutics is growing faster (85× against +4% a year earlier).
Which is more profitable, United Therapeutics or Nurix Therapeutics?
Nurix Therapeutics is more profitable, with an operating margin of 83.1% against 37.0%.
More: United Therapeutics earnings · how United Therapeutics makes money · Nurix Therapeutics earnings · how Nurix Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-Q filed Oct 13, 2026). Fiscal quarters can end on different dates. Not investment advice.